Huron Consulting Group Inc. — Q3 2023 Form 10-Q Summary
Business context and reporting period
Huron is a global professional services firm providing consulting, managed services, digital, technology, analytics, and software solutions through its Healthcare, Education, and Commercial segments. This unaudited Form 10-Q covers the three and nine months ended September 30, 2023, compared with the corresponding 2022 periods.
Key financial metrics
| Metric | Q3 2023 | Q3 2022 | 9M 2023 | 9M 2022 |
|---|
| Revenue | $358.2 million | $285.4 million | $1.023 billion | $818.7 million |
| Operating income | $37.3 million | $29.3 million | $95.5 million | $74.3 million |
| Operating margin | 10.4% | 10.3% | 9.3% | 9.1% |
| Net income | $21.5 million | $17.7 million | $59.6 million | $58.5 million |
| Diluted EPS | $1.10 | $0.86 | $3.05 | $2.80 |
| Adjusted EBITDA | $48.0 million | $36.5 million | $126.0 million | $91.8 million |
| Adjusted EBITDA margin | 13.4% | 12.8% | 12.3% | 11.2% |
- Q3 revenue increased 25.5%; nine-month revenue increased 24.9%.
- Q3 net income increased 21.3%, while diluted EPS increased 27.9%, benefiting from higher earnings and fewer diluted shares following repurchases.
- Nine-month net income increased only 2.0%, primarily because 2022 included a $27.0 million unrealized gain on the Medically Home preferred stock investment.
- Q3 utilization increased to 77.3% for Consulting and 75.4% for Digital, compared with 72.5% and 70.1%, respectively, in Q3 2022.
- Revenue-generating professionals increased to 5,341 from 4,571 at September 30, 2022.
Segment and capability performance
| Segment | Q3 2023 revenue growth | 9M 2023 revenue growth | 9M 2023 operating margin |
|---|
| Healthcare | 36.4% | 31.5% | 25.6% |
| Education | 17.7% | 23.8% | 23.7% |
| Commercial | 13.8% | 12.1% | 20.5% |
- Consulting and Managed Services revenue grew 37.7% in Q3 and 29.7% for the nine-month period.
- Digital revenue grew 10.8% in Q3 and 19.0% for the nine-month period.
- Healthcare was the primary growth contributor. Commercial revenue increased, but its nine-month operating margin declined from 22.0% to 20.5%.
Cash flow, balance sheet, debt, and liquidity
- Net cash provided by operating activities was $54.9 million for the first nine months of 2023, compared with cash used of $5.8 million in the prior-year period. Management attributed the improvement primarily to increased collections.
- Investing cash outflows were $25.8 million, including $19.6 million for internally developed software, $5.1 million for property and equipment, and $1.6 million for a business acquisition.
- Financing cash outflows were $31.5 million, including $88.9 million of share repurchases and $10.1 million of shares reacquired for employee tax withholding, partially offset by net borrowing activity.
- Cash and cash equivalents were $9.4 million at September 30, 2023, compared with $11.8 million at December 31, 2022.
- Receivables and unbilled services increased to $359.2 million from $289.6 million at year-end 2022, reflecting growth and timing differences between revenue recognition, billing, and collections.
- Debt outstanding under the senior secured revolving credit facility was $358.0 million, compared with $290.0 million at December 31, 2022. The weighted average interest rate was 4.4% versus 3.8%.
- Unused borrowing capacity was $241.4 million, and outstanding letters of credit totaled $0.6 million.
- The Company was in compliance with its debt covenants, reporting a Consolidated Leverage Ratio of 1.82x against a maximum of 3.75x and an Interest Coverage Ratio of 10.86x against a minimum of 3.00x.
- Management estimates 2023 property and equipment purchases and software development spending of approximately $35 million to $40 million.
Material changes versus the prior comparable period
- Revenue growth was broad-based, with particularly strong Healthcare performance and increased demand for Consulting and Managed Services.
- Operating margin improved modestly despite higher compensation, bonus, contractor, and technology costs.
- Q3 restructuring charges rose to $5.4 million from $1.3 million; nine-month charges rose to $9.4 million from $5.0 million. The 2023 charges included $5.4 million of non-cash office-related impairment charges, employee costs, and other facility costs.
- Interest expense increased to $15.1 million for the first nine months from $7.8 million, driven by higher rates and higher borrowings.
- The Company repurchased 1,116,830 shares for $88.4 million during the first nine months, representing approximately 5.6% of common shares outstanding at December 31, 2022. Approximately $21.1 million remained available under the then-current authorization.
- On September 1, 2023, Huron acquired Roundtable Analytics, Inc., a healthcare analytics company. The acquisition was not significant to the consolidated financial statements, and Huron issued 16,337 shares valued at $1.6 million as partial consideration.
- Management reported a $27.0 million unrealized Medically Home investment gain in the first quarter of 2022; no comparable gain occurred in 2023.
Outlook, commentary, risks, and unusual items
- Management’s stated strategy is to expand Healthcare and Education, grow Commercial, advance its digital platform, improve recurring revenue and margins, deploy capital strategically, and invest in personnel.
- Remaining performance obligations under engagements with original expected durations exceeding one year totaled $228.4 million at September 30, 2023. Management expected to recognize $25.8 million in 2023, $72.6 million in 2024, and $130.0 million thereafter; these amounts exclude certain variable consideration and time-and-expense arrangements.
- The filing does not provide a clear formal revenue or earnings guidance range. It does provide the capital-spending estimate noted above.
- Key risks include utilization, billing rates, demand volatility, client retention and renewals, employee recruitment and retention, technology and cybersecurity, privacy compliance, acquisitions and integration, goodwill impairment, taxes, market conditions, and interest-rate exposure.
- Huron uses interest-rate swaps covering $250.0 million of notional borrowings and foreign-exchange forwards related to Indian rupee expenses. A hypothetical 100-basis-point interest-rate change would affect annualized pretax income by approximately $1.1 million.
- Huron holds a Level 3 Shorelight convertible debt investment valued at $61.8 million and a Medically Home preferred stock investment carried at $33.6 million. These valuations involve significant assumptions and may fluctuate.
- Management stated that no litigation or claim was expected to have a material adverse effect, although litigation outcomes remain uncertain. No material off-balance-sheet arrangements were reported.
- Disclosure controls and procedures were deemed effective as of September 30, 2023, with no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether Healthcare-led demand and elevated utilization remain sustainable, particularly for performance-based engagements.
- Whether higher compensation, performance bonuses, and Commercial segment cost pressure affect future margins.
- Cash conversion and collection trends as unbilled services and receivables grow.
- Debt repayment capacity and sensitivity to higher interest rates, notwithstanding covenant compliance and available borrowing capacity.
- The extent and recurrence of restructuring charges and office-related impairments.
- The valuation and realizability of the Shorelight and Medically Home investments.
- Future share repurchases, including the impact of the fourth-quarter 2023 authorization increase from $300 million to $400 million and extension through December 31, 2024.
